{"entity":{"id":"nct02637531","kind":"trial","name":"A Dose-Escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of IPI-549","aka":[],"tldr":"A phase 1 trial of Eganelisib run by Infinity Pharmaceuticals, Inc., of unknown status on the registry.","summary":"A Dose-Escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of IPI-549 is a phase 1 interventional study registered as NCT02637531 by Infinity Pharmaceuticals, Inc., with 219 participants planned, started 2015-12. Conditions recorded: Advanced Solid Tumors (Part A/B/C/D), Non-small Cell Lung Cancer (Part E), Melanoma (Part E), Squamous Cell Cancer of the Head and Neck (Part E), Triple Negative Breast Cancer (Part F), Adrenocortical Carcinoma (Part G), Mesothelioma (Part G) and High-circulating Myeloid-derived Suppressor Cells (Part H). Interventions recorded: IPI-549 (eganelisib) and Nivolumab.","status":"historic","asOf":"2026-11-03","links":[{"label":"ClinicalTrials.gov NCT02637531","url":"https://clinicaltrials.gov/study/NCT02637531"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["metastatic-cancer","nsclc","melanoma","head-and-neck","tnbc","adrenocortical","mesothelioma"],"sections":[],"technologies":[],"targets":[],"drugs":["eganelisib"],"companies":["stelexis-biosciences"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT02637531","phase":"1","setting":"A Phase 1/1b First-In-Human, Dose-Escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of IPI-549 Monotherapy and in Combination With Nivolumab in Subjects With Advanced Solid Tumors","sponsor":"Infinity Pharmaceuticals, Inc.","enrolled":219,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct02637531/","neighbours":{"cancer":[{"id":"adrenocortical","kind":"cancer","name":"Adrenocortical carcinoma","route":"/cancers/adrenocortical/"},{"id":"head-and-neck","kind":"cancer","name":"Head and neck squamous cell carcinoma","route":"/cancers/head-and-neck/"},{"id":"melanoma","kind":"cancer","name":"Melanoma","route":"/cancers/melanoma/"},{"id":"mesothelioma","kind":"cancer","name":"Mesothelioma","route":"/cancers/mesothelioma/"},{"id":"metastatic-cancer","kind":"cancer","name":"Metastatic cancer (cancer that has spread)","route":"/cancers/metastatic-cancer/"},{"id":"nsclc","kind":"cancer","name":"Non-small-cell lung cancer","route":"/cancers/nsclc/"},{"id":"tnbc","kind":"cancer","name":"Triple-negative breast cancer (TNBC)","route":"/cancers/tnbc/"}],"drug":[{"id":"eganelisib","kind":"drug","name":"Eganelisib","route":"/drugs/eganelisib/"}],"company":[{"id":"stelexis-biosciences","kind":"company","name":"Stelexis BioSciences","route":"/companies/stelexis-biosciences/"}]}}